ArticleBMC cancer2020

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).

Hamza Hasan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.